Blueprint Medicines (BPMC) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Commercial performance and market opportunity

• AYVAKIT achieved a $0.5 billion revenue run rate in its first full year post-ISM launch, indicating strong market uptake and a shift in the treatment paradigm for indolent systemic mastocytosis (ISM).

• Diagnosed ISM patient numbers in the U.S. are rising, with claims data showing growth from 22,000 at the start of 2024, and updated epidemiology suggests higher disease prevalence than previously estimated.

• Expansion into new specialties, such as medical dermatology, is broadening the prescriber base, and misdiagnosed patients (e.g., IBS) are increasingly being correctly identified as ISM.

• 2024 revenue guidance was raised to $475–$480 million, driven by more patients starting and staying on therapy, favorable payer mix, and high compliance rates.

• European launch is progressing, with Germany as the largest contributor, and further country expansion underway.

Growth strategy and future outlook

• Continued growth is expected from both deepening engagement with current prescribers and expanding into additional specialties.

• The therapeutic area is highly promotionally sensitive, and ongoing field efforts are expected to drive further adoption.

• The company is in the early stages of a rare disease launch, anticipating market growth well into the next decade.

• IRA-related changes have optimized the commercial/free drug mix, with further affordability improvements expected in 2025 as out-of-pocket caps are smoothed.

• Treatment duration is long, with very low discontinuation rates and multi-year therapy expected; advanced SM patients show a 25-month average duration.

Pipeline and innovation

• Elenestinib is positioned as a next-generation therapy for SM, with a differentiated development strategy and a longer IP runway than AYVAKIT.

• The upcoming Harbor study for elenestinib aims to address future patient needs and build on real-world and clinical learnings.

• Elenestinib is expected to complement AYVAKIT, offering new value propositions and extending the franchise's lifecycle.

• BLU-808, a wild-type KIT inhibitor, targets chronic urticaria and broader Type 2 inflammatory diseases, with multiple proof-of-concept studies planned.

• Early clinical studies (SAD/MAD) for BLU-808 will inform dosing, safety, and pharmacodynamics, with tryptase as a key but not sole PD marker.